Abbott Labs Files 8-K on Financials

Ticker: ABT · Form: 8-K · Filed: 2025-01-22T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

Related Tickers: ABT

TL;DR

Abbott Labs dropped an 8-K on Jan 22 detailing financial results. Check it out.

AI Summary

Abbott Laboratories filed an 8-K on January 22, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 100 Abbott Park Road, Abbott Park, Illinois.

Why It Matters

This filing provides an update on Abbott Laboratories' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

This 8-K reports on Abbott Laboratories' Results of Operations and Financial Condition, and includes Financial Statements and Exhibits.

When was this 8-K filing submitted?

The filing was submitted on January 22, 2025.

Where are Abbott Laboratories' principal executive offices located?

The principal executive offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.

What is the company's IRS Employer Identification Number?

The IRS Employer Identification Number for Abbott Laboratories is 36-0698440.

What is the SIC code for Abbott Laboratories?

The Standard Industrial Classification code for Abbott Laboratories is 2834, Pharmaceutical Preparations.

From the Filing

0001628280-25-002092.txt : 20250122 0001628280-25-002092.hdr.sgml : 20250122 20250122071321 ACCESSION NUMBER: 0001628280-25-002092 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250122 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250122 DATE AS OF CHANGE: 20250122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 25543881 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20250122.htm 8-K abt-20250122 0000001800 FALSE New York Stock Exchange Chicago Stock Exchange, Inc. 0000001800 2025-01-22 2025-01-22 0000001800 exch:XCHI 2025-01-22 2025-01-22 0000001800 exch:XNYS 2025-01-22 2025-01-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 _______________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2025 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) _______________________________________________________ Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification  No.) _______________________________________________________ 100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: ( 224 ) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition On January 22, 2025, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, a divestiture, restructuring actions, fair value adjustments to the

View on Read The Filing